


NCT-506

Cat. No.:	HY-112278
CAS No.:	2231098-99-8
Molecular Formula:	C ₂₅ H ₂₃ FN ₄ O ₃ S
Molecular Weight:	478.54
Target:	Aldehyde Dehydrogenase (ALDH)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	NCT-506 is an orally bioavailable aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with an IC ₅₀ of 7 nM ^[1] .								
In Vitro	<p>NCT-506 inhibits ALDH1A1, hALDH1A3, hALDH2 with IC₅₀s of 0.007±0.001, 16.4±3.99, and 21.5 μM, respectively^[1]. NCT-506 (100, 10, 1, 0.1 μM, 6 days) decreases significantly cell viability with an EC₅₀ of 45.6 μM in OV-90 cells. NCT-506 inhibits MIA PaCa-2, OV-90, and HT-29 cells with IC₅₀s of 0.077±0.040, 0.161±0.038, and 0.048±0.022 μM in aldefluor cell-based assays, respectively^[1].</p> <p>NCT-506 is treated in combined with Paclitaxel, IC₅₀s of 1202, 924, 870, 411, 102, and 31.8 nM with concentrations of NCT-506 at 0 (DMSO), 1, 3, 10, 20, 30 μM in SKOV-3-TR cells, respectively^[1].</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>OV-90 and SKOV-3-TR cells</td> </tr> <tr> <td>Concentration:</td> <td>100, 10, 1, 0.1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>6 days for OV-90 cells; 4 days for SKOV-3-TR cells</td> </tr> <tr> <td>Result:</td> <td>Decreased significantly cell viability with an EC₅₀ of 45.6 μM in OV-90 cells. Decreased cell viability in combined treatments (Paclitaxel concentration of 100 nM) with an EC₅₀ of 11.2 μM in SKOV-3-TR cells.</td> </tr> </table>	Cell Line:	OV-90 and SKOV-3-TR cells	Concentration:	100, 10, 1, 0.1 μM	Incubation Time:	6 days for OV-90 cells; 4 days for SKOV-3-TR cells	Result:	Decreased significantly cell viability with an EC ₅₀ of 45.6 μM in OV-90 cells. Decreased cell viability in combined treatments (Paclitaxel concentration of 100 nM) with an EC ₅₀ of 11.2 μM in SKOV-3-TR cells.
Cell Line:	OV-90 and SKOV-3-TR cells								
Concentration:	100, 10, 1, 0.1 μM								
Incubation Time:	6 days for OV-90 cells; 4 days for SKOV-3-TR cells								
Result:	Decreased significantly cell viability with an EC ₅₀ of 45.6 μM in OV-90 cells. Decreased cell viability in combined treatments (Paclitaxel concentration of 100 nM) with an EC ₅₀ of 11.2 μM in SKOV-3-TR cells.								

REFERENCES

[1]. Yang SM, et al. Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity. J Med Chem. 2018 Jun 14;61(11):4883-4903.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA